Our friends at Alliance Defending Freedom filed the original suit in November 2022 and represent over 30,000 medical professionals from four national medical associations, and several more independent doctors. ADF argues that because the FDA has never tested the drug on the pediatric population, there is no science backing its safety for use in young women. Dr. Christina Francis, the CEO-Elect of the American Association of Pro-Life Obstetricians and Gynecologists and a party in the suit, stated in an interview that Mifepristone is not only untested, but dangerous. She reports that 1 in 5 women have serious complications following chemical abortions including hemorrhage, life-threatening infection and fertility issues.
In their brief, the attorneys general argue in part that the FDA’s approval of mifepristone for abortion has two legal flaws. The first is that it defies the agency’s own regulations since the section the FDA first approved the drug under, Subpart H, “does not permit the agency to greenlight elective abortions on a wide scale.” The second is that allowing abortion medication to be sent via the mail is in direct contrast to a federal law that prohibits “using the mail to send or receive abortion-inducing drugs such as mifepristone.” They go on to state, “The FDA and the Administration as a whole have no intention to respect the Constitution, the Supreme Court, or the democratic process when it comes to abortion.”
The lawsuit is asking the court to revoke the FDA’s approval of mifepristone completely. If this does not happen, they are asking that laws and regulations be followed at all stages in regard to reviewing, approving, prescribing, dispensing, and administering chemical abortion drugs. If the judge doesn’t rule against mifepristone entirely, the lawsuit asks that current laws and regulations be followed in regard to these chemicals.
The State of Missouri filed its own brief on Friday, February 10th, while Mississippi Attorney General Lynn Fitch filed a brief on behalf of her state as well as Alabama, Alaska, Arkansas, Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Montana, Nebraska, Ohio, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, and Wyoming.
The U.S. Justice Department argued in its court filing this lawsuit “is extraordinary and unprecedented.” The United States District Court for the Northern District of Texas will hear the case first. After this, an appeal would likely go to the 5th U.S. Circuit Court of Appeals, and if a ruling in that court were to be appealed, it could go to the U.S. Supreme Court.
North Carolina Attorney General Josh Stein, who recently announced that he will be running for governor in 2024, has made it clear that his office will not support efforts to restrict abortion or abortion-inducing drugs in North Carolina. While North Carolina does have stricter regulations for chemical abortions than many other states, the ability to receive mifepristone via the mail reduces the impact of these laws. Based on data from 2020 when there were 30,004 abortions reported in the state, 59% of North Carolina resident abortions were chemical. If this lawsuit results in the revocation of the approval of mifepristone, many lives will be saved.